Jim Simons Intra Cellular Therapies, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 222,400 shares of ITCI stock, worth $16.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

222,400

Previous 96,700 129.99%

Holding current value

$16.1 Million

Previous $6.69 Million 127.62%

% of portfolio

0.03%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$64.76 - $79.84 $8.14 Million - $10 Million	125,700 Added 129.99%	222,400 $15.2 Million
Q1 2024 May 13, 2024	SELL	$64.37 - $75.65 $3.59 Million - $4.21 Million	-55,700 Reduced 36.55%	96,700 $6.69 Million
Q4 2023 Feb 13, 2024	SELL	$46.37 - $73.65 $5.17 Million - $8.22 Million	-111,600 Reduced 42.27%	152,400 $10.9 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $1.22 Million - $1.51 Million	23,500 Added 9.77%	264,000 $13.8 Million
Q2 2023 Aug 11, 2023	BUY	$54.67 - $66.44 $13.1 Million - $16 Million	240,500 New	240,500 $15.2 Million
Q2 2020 Aug 13, 2020	SELL	$14.35 - $26.64 $2.17 Million - $4.03 Million	-151,400 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$12.31 - $33.12 $1.86 Million - $5.01 Million	151,400 New	151,400 $2.33 Million
Q3 2019 Nov 13, 2019	SELL	$7.47 - $14.03 $614,781 - $1.15 Million	-82,300 Closed	0 $0
Q2 2019 Aug 12, 2019	SELL	$10.65 - $14.29 $17,040 - $22,864	-1,600 Reduced 1.91%	82,300 $1.07 Million
Q1 2019 May 14, 2019	SELL	$10.9 - $14.09 $609,310 - $787,631	-55,900 Reduced 39.99%	83,900 $1.02 Million
Q4 2018 Feb 13, 2019	BUY	$10.36 - $20.96 $1.45 Million - $2.93 Million	139,800 New	139,800 $1.59 Million

Others Institutions Holding ITCI

# of Institutions

400

Shares Held

87.2M

Call Options Held

309K

Put Options Held

302K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.84B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account